RxDoctor Payments Data

Afsanah Widner, PA

Physician Assistant · Roanoke, VANPI 1972872547

Payments from drug & device makers

$512in general payments, 2019–2025

Across 16 payments — averaging $31.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$214
  • Novo Nordisk$97
  • GSK$51
  • Otsuka America Pharmaceutical, Inc.$37
  • Pfizer$31
  • Gilead$28
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$512100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$512 in reported general payments places this provider in the 60th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$629
Medicare patients
20
Services billed
51

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide106$126,101
JardianceEmpagliflozin66$60,928
OzempicSemaglutide38$51,202
JanuviaSitagliptin Phosphate45$39,399
EliquisApixaban37$33,349
Spiriva HandihalerTiotropium Bromide25$23,043
Breo ElliptaFluticasone/Vilanterol15$9,992
Levemir FlexpenInsulin Detemir19$9,335
Incruse ElliptaUmeclidinium Bromide20$8,679
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$8,245
SymbicortBudesonide/Formoterol Fumarate31$7,480
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$7,152
LyricaPregabalin11$5,881
Novolog FlexpenInsulin Aspart20$4,722
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate27$4,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$97$51,20238 claims
PfizerEliquis, Lyrica$31$39,23048 claims
GSKBreo Ellipta, Incruse Ellipta, Anoro Ellipta$51$26,91654 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →